OR-NUSCALE-POWER
23.9.2021 15:47:14 CEST | Business Wire | Press release
NuScale Power, KGHM Polska Miedź S.A. (KGHM), and Piela Business Engineering (PBE) announced today the three companies have signed a Memorandum of Understanding (MOU) to explore the deployment of NuScale’s small modular reactor (SMR) technology as a coal repurposing solution for existing coal-fired power plants and electricity and heat for KGHM’s industrial processes in Poland. KGHM is a Poland-based leader in copper and silver production and PBE is a Poland-based consultancy which specializes in business engineering advisory. This agreement demonstrates international interest in utilizing NuScale’s SMR technology to produce clean, reliable, and affordable energy.
Under the MOU, NuScale will support KGHM and PBE’s examination of NuScale’s SMR technology as a coal repowering/repurposing solution for existing coal-fueled power plants and more broadly for new nuclear plant implementations, as well as for energy in support of industrial operations in Poland. The examination will include an analysis of technical, economic, legal, regulatory, financial, and organizational factors.
“NuScale is thrilled to partner with KGHM and PBE on the potential deployment of NuScale Power plants in Poland,” said John Hopkins, Chairman and CEO of NuScale Power. “The retirement of aging coal-fired power plants is leading to changes in power generation, infrastructure needs, and workforce opportunity. NuScale’s SMR technology is an ideal flexible clean energy solution to repurpose retiring coal fueled power plants and most importantly, retain and retrain the skilled power plant workforce already in place in these Polish communities.”
“The changes in the climate are forcing us to take decisive actions. We are already feeling the impact, including in a financial sense, connected among others with the increases in energy prices. The construction of small nuclear reactors by 2030 is a solid declaration and an element of our energy transformation. We are pioneers in Poland, as we expect that the first of our nuclear power plants will come online in 2029,” said Marcin Chludziński, President of the Management Board of KGHM Polska Miedź S.A. “SMR technology will not only help us to protect the environment but will also substantially reduce the costs of operating our business. This is one of the recently-announced initiatives aimed at growing the company, and we plan to generate power commercially in order to assist in the green transformation of Poland and bring down costs for the average household,” added President Chludziński.
“With the future energy sector, design modular energy sources will play an exceptionally important role,” said Piotr Piela, Founder and Managing Partner of PBE. “This is why the SMR, which is not competitive but truly complementary to big nuclear reactors, is not only a crucial component fitting energy transformation of Poland and many others fossil fuels dependent European Union (EU) countries, but also considered the ‘technology of common interest’ essential to successfully implement the Pan European Green Deal.”
In August 2020, NuScale made history as the first and only SMR to receive design approval from the U.S. Nuclear Regulatory Commission and in July of 2021, the Commission published the proposed rule that would certify the NuScale design – a crucial step towards the construction and deployment of this SMR technology. The company maintains strong program momentum toward commercialization of its SMR technology, including supply chain development, standard plant design, planning of plant delivery activities, and startup and commissioning plans.
About NuScale Power
NuScale Power has developed a new modular light water reactor nuclear power plant to supply energy for electrical generation, district heating, desalination, hydrogen production and other process heat applications. This groundbreaking small modular reactor (SMR) design features a fully factory-fabricated NuScale Power Module™ capable of generating 77 MW of electricity using a safer, smaller, and scalable version of pressurized water reactor technology. NuScale's scalable design—power plants that can house up to four, six, or 12 individual power modules—offers the benefits of carbon-free energy and reduces the financial commitments associated with gigawatt-sized nuclear facilities. The majority investor in NuScale is Fluor Corporation, a global engineering, procurement, and construction company with a 70-year history in commercial nuclear power.
NuScale is headquartered in Portland, OR and has offices in Corvallis, OR; Rockville, MD; Charlotte, NC; Richland, WA; and London, UK. Follow us on Twitter: @NuScale_Power , Facebook: NuScale Power, LLC , LinkedIn: NuScale-Power , and Instagram: nuscale_power . Visit NuScale Power's website .
About KGHM Polska Miedź S.A.
KGHM is involved in the mining and processing of valuable natural resources. At its heart is the largest deposit of copper ore in Europe, located in south-western Poland. By advancing our strategy we are systematically strengthening KGHM’s international position. Currently the company has a geographically diversified mine project profile. It has operations on three continents – in Europe, North America and South America. The copper ore resources controlled by KGHM guarantee the company a leading position in the mining industry. Our portfolio includes metals such as molybdenum, palladium and nickel, opening the way for KGHM to gain a strong position amongst the world’s diversified miners. www.kghm.com
About Piela Business Engineering
Piela Business Engineering is a Poland based consulting firm providing strategic, operational, engineering and regulatory advisory, primarily focused on energy and chemical sectors. For over 20 years, PBE’s experts have participated in the processes related to the climate and energy transformation and the implementation of the circular economy, working for governments, financial institutions, regulators and enterprises in Poland and abroad. The realized projects included policy papers, strategic studies, feasibility studies, but also full scope preparation of investment projects for implementation.
PBE's experts have been involved in the development of the Nuclear Power Program in Poland since early 2009. www.pbe-molecule.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005575/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom